India’s first COVID-19 vaccine candidate COVAXIN gets DCGI approval

ForumIAS announcing GS Foundation Program for UPSC CSE 2025-26 from 19 April. Click Here for more information.

ForumIAS Answer Writing Focus Group (AWFG) for Mains 2024 commencing from 24th June 2024. The Entrance Test for the program will be held on 28th April 2024 at 9 AM. To know more about the program visit: https://forumias.com/blog/awfg2024

News: India’s first COVID-19 vaccine candidate COVAXIN has received the approval of Drug Controller General of India(DCGI) for phase I and II of human clinical trials.

Facts:

  • COVAXIN: It is an inactivated vaccine created from a strain of the infectious SARS-CoV-2 virus.
  • Developed by: It has been developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV).

Additional Facts:

  • DGCI: It is a department of the Central Drugs Standard Control Organization(CDSCO) responsible for approval of licences of specified categories of drugs such as blood and blood products, IV fluids and vaccines in India.It comes under the Ministry of Health & Family Welfare.
Print Friendly and PDF
Blog
Academy
Community